Supercede Therapeutics Inc. has released preclinical efficacy data on its small-molecule inhibitor of the Activin receptor type II (ACTRII) to treat obesity.
Cue Biopharma Inc. has received pre-IND feedback from the FDA to discuss the proposed development plan for CUE-401, its lead autoimmune asset. Based on FDA feedback, the company intends to file an IND pending completion of final IND-enabling studies.
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, Chinese Academy of Medical Sciences and Peking Union Medical College scientists co-presented a carbonic anhydrase IX (CAIX)-targeting 68Ga/177Lu theranostic pair for clear cell renal cell carcinoma (ccRCC) and its preclinical evaluation.
Work at Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has led to the identification of new protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
CNCCS SCARL Collezione Nazionale Dei Composti Chimici E Centro Screening and IRBM SpA have prepared new serine protease NS3/non-structural protein 2B (NS3/NS2B) (dengue virus) and/or (West Nile virus) and/or (Zika virus) and/or Japanese encephalitis virus inhibitors.
Impact Therapeutics Inc. has disclosed new heteroaromatic and heterobicyclic compounds acting as Myt1 kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
RSS
